DE69430695T2 - Verfahren zur verbesserung der wahrnehmung mit partiellen agonisten des glycin/nmda-rezeptorkomplexes - Google Patents
Verfahren zur verbesserung der wahrnehmung mit partiellen agonisten des glycin/nmda-rezeptorkomplexesInfo
- Publication number
- DE69430695T2 DE69430695T2 DE69430695T DE69430695T DE69430695T2 DE 69430695 T2 DE69430695 T2 DE 69430695T2 DE 69430695 T DE69430695 T DE 69430695T DE 69430695 T DE69430695 T DE 69430695T DE 69430695 T2 DE69430695 T2 DE 69430695T2
- Authority
- DE
- Germany
- Prior art keywords
- nmda receptor
- receptor complex
- salts
- glycin
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 title abstract 4
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title abstract 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title abstract 2
- 239000004031 partial agonist Substances 0.000 title 1
- 230000008447 perception Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 4
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- UAWVRVFHMOSAPU-UHFFFAOYSA-N 7-chlorokynurenic acid Chemical compound C1=CC(Cl)=CC2=NC(C(=O)O)=CC(O)=C21 UAWVRVFHMOSAPU-UHFFFAOYSA-N 0.000 abstract 1
- 208000002381 Brain Hypoxia Diseases 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 208000029028 brain injury Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/003,225 US5428069A (en) | 1993-01-11 | 1993-01-11 | Treating cognition with, aminocyclopropanecarboxylic derivatives |
| PCT/US1994/000235 WO1994015598A2 (en) | 1993-01-11 | 1994-01-07 | Methods for the improvement of cognition with functional antagonists of the glycine nmda receptor complex |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69430695D1 DE69430695D1 (de) | 2002-07-04 |
| DE69430695T2 true DE69430695T2 (de) | 2002-09-12 |
Family
ID=21704805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69430695T Expired - Fee Related DE69430695T2 (de) | 1993-01-11 | 1994-01-07 | Verfahren zur verbesserung der wahrnehmung mit partiellen agonisten des glycin/nmda-rezeptorkomplexes |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5428069A (de) |
| EP (1) | EP0678021B1 (de) |
| JP (1) | JPH08510990A (de) |
| AT (1) | ATE218061T1 (de) |
| AU (1) | AU679492B2 (de) |
| CA (1) | CA2153596A1 (de) |
| DE (1) | DE69430695T2 (de) |
| WO (1) | WO1994015598A2 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854217A (en) | 1992-09-28 | 1998-12-29 | Bearsden Bio, Inc. | Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function |
| GB9311948D0 (en) * | 1993-06-10 | 1993-07-28 | Zeneca Ltd | Substituted nitrogen heterocycles |
| US5801168A (en) * | 1994-06-09 | 1998-09-01 | Zeneca Limited | Substituted nitrogen heterocycles |
| ES2260773T3 (es) * | 1995-12-07 | 2006-11-01 | Daniel C. Javitt | Tratamiento de los sintomas negativos y cognitivos de la esquizofreniacon antagonistas de la absorcion de glicina. |
| US6361957B1 (en) * | 1999-08-03 | 2002-03-26 | Glytech, Inc. | Assay for D-serine transport antagonist and use for treating psychosis |
| US6355681B2 (en) * | 1995-12-07 | 2002-03-12 | Glytech, Inc. | Glycine substitutes and precursors for treating a psychosis |
| US5763393A (en) * | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| JP2002513380A (ja) | 1996-07-22 | 2002-05-08 | コグネティックス・インコーポレイテッド | コナントキンの使用 |
| US6277825B1 (en) | 1996-07-22 | 2001-08-21 | University Of Utah Research Foundation | Use of conantokins for treating pain |
| JP2001507924A (ja) | 1996-07-22 | 2001-06-19 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション | コナントキン類 |
| US5906976A (en) * | 1996-10-22 | 1999-05-25 | Ramot-University Authority For Applied Research And Industrial Development, Ltd. | Method and composition for treating neuronal degeneration |
| US6399574B1 (en) | 2000-03-22 | 2002-06-04 | University Of Utah Research Foundation | Use of conantokins |
| WO2002078629A2 (en) * | 2001-03-29 | 2002-10-10 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| US20030022253A1 (en) * | 2001-07-25 | 2003-01-30 | Nyxis Neurotherapies, Inc. | Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby |
| KR20070007276A (ko) | 2003-12-29 | 2007-01-15 | 제이슨 맥데빗 | 재발성 의학적 증상을 치료하기 위한 조성물 및 방법 |
| US20060084659A1 (en) * | 2004-10-19 | 2006-04-20 | Michael Davis | Augmentation of psychotherapy with cannabinoid reuptake inhibitors |
| JP2006213611A (ja) * | 2005-02-02 | 2006-08-17 | Suzuka Univ Of Medical Science | １‐アミノシクロプロパンカルボン酸等を主成分とする脳卒中又は脳卒中後遺症の予防用又は治療用薬剤 |
| WO2008013860A2 (en) * | 2006-07-28 | 2008-01-31 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use |
| US9737562B2 (en) | 2012-12-11 | 2017-08-22 | The Mclean Hospital Corporation | Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554017A (en) * | 1978-06-03 | 1985-11-19 | Bayer Aktiengesellschaft | Method and compositions for regulating plant growth using cycloalkane-carboxylic acid compounds |
| US4788332A (en) * | 1987-08-05 | 1988-11-29 | General Foods Corporation | L-aminodicarboxylic acid esters |
| US4781927A (en) * | 1985-04-15 | 1988-11-01 | General Foods Corporation | Sweetening with l-aminodicarboxylic acid esters |
| US4822653A (en) * | 1987-08-05 | 1989-04-18 | National Starch And Chemical Corporation | Recyclable hot melt adhesive compositions |
| US4904681A (en) * | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
| US6017957A (en) * | 1989-08-08 | 2000-01-25 | The United States Of America As Represented By The Department Of Health And Human Services | Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents |
| US5086072A (en) * | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
-
1993
- 1993-01-11 US US08/003,225 patent/US5428069A/en not_active Expired - Fee Related
-
1994
- 1994-01-07 EP EP94906547A patent/EP0678021B1/de not_active Expired - Lifetime
- 1994-01-07 JP JP6516227A patent/JPH08510990A/ja not_active Ceased
- 1994-01-07 DE DE69430695T patent/DE69430695T2/de not_active Expired - Fee Related
- 1994-01-07 AU AU60228/94A patent/AU679492B2/en not_active Ceased
- 1994-01-07 WO PCT/US1994/000235 patent/WO1994015598A2/en active IP Right Grant
- 1994-01-07 AT AT94906547T patent/ATE218061T1/de not_active IP Right Cessation
- 1994-01-07 CA CA002153596A patent/CA2153596A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU6022894A (en) | 1994-08-15 |
| WO1994015598A3 (en) | 1994-09-15 |
| JPH08510990A (ja) | 1996-11-19 |
| CA2153596A1 (en) | 1994-07-21 |
| EP0678021A1 (de) | 1995-10-25 |
| EP0678021B1 (de) | 2002-05-29 |
| US5428069A (en) | 1995-06-27 |
| WO1994015598A2 (en) | 1994-07-21 |
| DE69430695D1 (de) | 2002-07-04 |
| AU679492B2 (en) | 1997-07-03 |
| ATE218061T1 (de) | 2002-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69430695D1 (de) | Verfahren zur verbesserung der wahrnehmung mit partiellen agonisten des glycin/nmda-rezeptorkomplexes | |
| MY130145A (en) | Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders. | |
| HK50996A (en) | Treatment of gastrointestinal disorders using 5-ht3 antagonists | |
| HUP9900508A2 (hu) | 2-Amino-4-(4-fluor-benzil-amino)-1-(etoxi-karbonil-amino)-benzol alkalmazása agyi vérellátási zavarok, valamint neurodegeneratív megbetegedések következményeinek megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására | |
| UA41906C2 (uk) | Спосіб лікування неврологічних порушень, викликаних травмами | |
| MY101863A (en) | Carbocyclic or heterocyclic carboxylic acid esters and amides of a cyclic alkohol and its use in the treatment of psychiatric disorders | |
| EP0383504A3 (de) | Decahydroisoquinolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente | |
| PL330207A1 (en) | Aryl-substituted cyclic amines as selective ligands of d 3 dopamine | |
| DE69623271T2 (de) | Verwendung von imidazo-(1,2-a)-pyridin-3-acetamid-derivaten für die therapeutische behandlung von neuropsychiatrischen syndromen in zusammenhang mit störungen der nervenbahnen der basalganglien | |
| EP0451654A3 (en) | Use of n-alkylated 1,4-dihydropyridine carboxylic acid esters as drugs, new compounds and process for their preparation | |
| HUT50782A (en) | Process for producing bicyclic amines | |
| HU9502848D0 (en) | Imidazoloquinoxalinone derivatives as eaa antagonists | |
| DE3780542D1 (en) | Substituierte hexahydroarylchinolizine. | |
| ES8602731A1 (es) | Un procedimiento para la preparacion de derivados del acido 4-(((alcoxi sustituido)carbonil)-amino)-4,5-dihidro-2-furan-carboxilico | |
| MY100953A (en) | Treatment of gastrointestinal disorders | |
| NO951865L (no) | Quinuclidin-derivat som substans-P antagonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8339 | Ceased/non-payment of the annual fee |